Printer Friendly

AMGEN AND CHUGAI REACH AGREEMENT ON G-CSF PATENT DISPUTE

 AMGEN AND CHUGAI REACH AGREEMENT ON G-CSF PATENT DISPUTE
 THOUSAND OAKS, Calif., May 12 /PRNewswire/ -- Amgen (NASDAQ: AMGN)


announced today that it has reached an agreement with Chugai Pharmaceuticals Inc. to resolve the ongoing disputes regarding intellectual property rights relating to granulocyte colony-stimulating factor (G-CSF). These agreements are subject to both parties obtaining final consents and approvals from each party's licensees and partners.
 The terms of the agreement for the United States provide that the case pending in the United States District Court for the District of Columbia (No. 92-CV-170) will be resolved by Chugai's disclaimer of the two patents in their entirety that were the subject of the action. In addition, Chugai will grant Amgen an irrevocable exclusive, royalty-free license for all of the remaining G-CSF patent rights Chugai may have in the United States. Chugai is also withdrawing from the patent interference proceeding currently pending in the United States Patent Office (Interference No. 102,396).
 Separately, Chugai will grant Amgen an irrevocable, royalty-free exclusive license for all G-CSF patent rights in Canada and Mexico. In Europe, Australia and New Zealand, the parties will enter into covenants not to sue each other with respect to all of their G-CSF patent rights. These covenants will also apply to each party's affiliates, joint venturers, subsidiaries and licensees.
 In Japan, Taiwan and Korea, Chugai and Kirin Brewery Co. Ltd. have agreed to enter into similar covenants not to sue.
 In the People's Republic of China, Amgen, Kirin and Chugai have agreed to enter into similar covenants for all of their G-CSF patent rights. These covenants will also apply to each party's affiliates, joint venturers, subsidiaries and licensees.
 In certain other countries Chugai and F. Hoffmann-La Roche Ltd. have agreed to enter into similar covenants not to sue.
 Amgen Inc. is a global pharmaceutical company that develops, manufactures and markets human pharmaceuticals based on advanced cellular and molecular biology.
 -0- 5/12/92
 /CONTACT: Sarah H. Crampton (investors), 805-499-5725 ext. 3250, or Kimberly L. Dorsey (media), 805-499-5725 ext. 4367, both of Amgen/
 (AMGN) CO: Amgen Inc.; Chugai Pharmaceuticals Inc. ST: California IN: MTC SU:


KJ -- LA030 -- 9416 05/12/92 18:56 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1992
Words:360
Previous Article:HARKEN ANNOUNCES FIRST QUARTER RESULTS
Next Article:CHEVRON ACQUIRES 23 EXXON STATIONS IN LOS ANGELES
Topics:


Related Articles
GENETICS INSTITUTE AND AMGEN SETTLE EPO DISPUTE
Protein Design Labs Announces Multiple Humanization Patent License Agreements With Chugai.
LEAD: Court rejects Ajinomoto's appeal against Chugai in patent case.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters